abstract: We identified three doublesex and mab-3-related transcription factors (DMRT) that were sexually differentially expressed in human fetal gonads and present in the ovaries at the time of meiotic initiation. These were also identified in murine embryonic female germ cells. Among these, we focused on DMRTA2 (DMRT5), whose function is unknown in the developing gonads, and clarified its role in human female fetal germ cells, using an original xenograft model. Early human fetal ovaries (8-11 weeks post-fertilization) were grafted into nude mice. Grafted ovaries developed normally, with no apparent overt changes, when compared with ungrafted ovaries at equivalent developmental stages. Appropriate germ cell density, mitotic/meiotic transition, markers of meiotic progression and follicle formation were evident. Four weeks after grafting, mice were treated with siRNA, specifically targeting human DMRTA2 mRNA. DMRTA2 inhibition triggered an increase in undifferentiated FUT4-positive germ cells and a decrease in the percentage of meiotic gH2AX-positive germ cells, when compared with mice that were injected with control siRNA. Interestingly, the expression of markers associated with pre-meiotic germ cell differentiation was also impaired, as was the expression of DMRTB1 (DMRT6) and DMRTC2 (DMRT7). This study reveals, for the first time, the requirement of DMRTA2 for normal human female embryonic germ cell development. DMRTA2 appears to be necessary for proper differentiation of oogonia, prior to entry into meiosis, in the human species. Additionally, we developed a new model of organ xenografting, coupled with RNA interference, which provides a useful tool for genetic investigations of human germline development.
Introduction
In mammals, female reproductive potential is dictated in part, by the proper development of the germline during fetal life. Indeed in the fetal ovary, germ cells, also termed oogonia, initially proliferate very actively before entering into meiosis to make up the definitive pool of nonrenewable oocytes that will sustain female fertility throughout adulthood (Mamsen et al., 2011) . This crucial step occurs only once during the female lifespan. Most of our knowledge of the mechanisms that sustain the development of germ cells arises from murine studies, and little is known about such mechanisms in larger mammals, including humans. Interestingly, the development of the human fetal ovary appears to be a much slower process than that of the mouse, requiring several weeks instead of a few days. Moreover, the human cycle is asynchronous, featuring the co-existence of germ cells at various stages of differentiation (i.e. oogonia, oocytes and follicles). In human fetal gonads, primordial germ cells (PGCs) colonize the genital anlage between the end of the fifth and sixth weeks post-fertilization (wpf) (Motta et al., 1997) .
The PGCs then differentiate into oogonia, with only proliferating oogonia being observed until around 10 wpf. At 11 wpf, the first signs of meiosis initiation become apparent and later, somatic cells organize into cellular cordlike structures, which envelope nests of germ cells within the cortical zones (Motta et al., 1997; Le Bouffant et al., 2010; Childs et al., 2011) . While increasing numbers of germ cells initiate meiosis, a pool of oogonia carry on proliferating until at least 16-20 wpf. At around 20 wpf, some oocytes become enclosed into primordial follicles (Francavilla et al., 1990) . As in the mouse model, in humans, germ cell differentiation is a gradual process, as demonstrated by the progression of marker expression from oogonia to primordial follicles (Stoop et al., 2005) . PGCs first express pluripotent stem cell markers such as NANOG, FUT4/SSEA1 or POU5F1/OCT4, when they reach the genital ridge (Kerr et al., 2008) . Oogonia gradually progress from their undifferentiated state and express the germ cell lineage marker DDX4. Simultaneously they acquire the ability to initiate sexual differentiation and enter meiosis, as evidenced through DAZL expression (Anderson et al., 2007; Lin et al., 2008) . The expression of the meiosis gatekeeper STRA8 can be detected shortly thereafter (Le Bouffant et al., 2010; Childs et al., 2011) . During the course of oogonia differentiation and before meiotic entry, germ cells loose the expression of the stem cell markers (Kerr et al., 2008) .
The doublesex (dsx) and male abnormal-3 (mab-3) related transcription factor (DMRT) gene family consists of 8 member genes, which are conserved among vertebrates and widely involved in developmental processes including somitogenesis, nervous system development and gonadal differentiation (Zarkower, 2013) . Interestingly, Dmrt1, the most well-known member of this family, has recently been identified as being involved in regulating male fetal germ cell proliferation and pluripotency, and controlling the mitosis/meiosis decision in adult mouse spermatogonia (Raymond et al., 2000; Kim et al., 2007a; Krentz et al., 2009; Matson et al., 2010; Matson and Zarkower, 2012) . In the mouse ovary, Dmrt1 has been shown to directly activate the transcription of Stra8 (Krentz et al., 2011) . In humans, DMRT1 is expressed in male and female fetal gonads and adult testes (Jorgensen et al., 2012) , and loss of DMRT1 has been proposed as being associated with sex reversal, gonadal failure and testicular germ cell tumors (Bennett et al., 1993; Lopes et al., 2013; Quinonez et al., 2013) . However, its role in human fertility remains poorly understood.
It has been demonstrated that other members of the DMRT family are involved in organogenesis, including gametogenesis; Dmrta1 (Dmrt4) appears to play a role in folliculogenesis (Balciuniene et al., 2006) , Dmrtb1 (Dmrt6) expression is essential during meiotic prophase I of spermatogonia (Zarkower, 2013) and Dmrtc2 (Dmrt7) purportedly plays a role in the recruitment of chromatin marks to the sex chromosomes (Kim et al., 2007b) . However, to date Dmrta2 (Dmrt5) has only been shown to be involved in central nervous system development (Guo et al., 2004; Konno et al., 2012; Saulnier et al., 2013) , despite expression being demonstrated in murine fetal ovaries and adult testes (Kim et al., 2003) .
To understand better the role of the DM domain gene family in human gonad development, we investigated the expression of these genes. DMRTA2 (DMRT5) expression was well correlated with meiosis initiation. In order to explore its role during the mitotic/ meiotic transition, we developed an original model of xenografted human fetal ovaries in immunodeficient mice, coupled with RNA interference.
Materials and Methods

Experimental animals
All animal studies were conducted in accordance with the French Ministry of Agriculture guidelines for the care and use of laboratory animals. NMRI (Naval Maritime Research Institute) mice were used to harvest gonads at various developmental stages as previously described . The Pou5f1-GFP mouse model, used for cell sorting, was previously described (Yoshimizu et al., 1999) . Female immunodeficient NMRI:Nu/Nu mice, 6 -8 weeks old, were used as recipient animals for xenografts.
Collection of murine gonads
Fetal and postnatal murine gonads were harvested from fetal stage 11.5 days post conception (dpc) until adulthood (60 days post-partum (dpp)). Males were caged with females overnight, and the presence of vaginal plug was examined the following morning. Pregnant females were sacrificed by cervical dislocation and their fetuses were removed from uterine horns. The sex of gonads before 12.5 dpc was determined by PCR amplification of Sry as previously described (Petre-lazar et al., 2007) . For fetal stages each sample represents a pool of 3 -8 gonads. Apart for the adult gonads, all observations of postnatal stages were made on pools of three gonads. At 60 dpp the ovary was used as a whole and one-fourth of the testis was used. All tissues were stored at 2208C in lysis buffer (Buffer RLTw, guanidine thiocyanate buffer, RNeasy mini-kit, Qiagen Courtaboeuf, France) immediately after harvesting.
Collection of human fetal gonads
Human fetal ovaries were harvested from material obtained following legally induced abortions, carried out during the first trimester of pregnancy, or therapeutic terminations, carried out during the second or third trimesters of pregnancy, i.e. from 6 to 22 wpf. The operations were done in the Department of Obstetrics and Gynecology at the Antoine Béclère Hospital, Clamart (France) as previously described (Guerquin et al., 2009; Le Bouffant et al., 2010) . Fetal age was calculated by measuring the length of limbs and feet according to the mathematical model developed by Evtouchenko et al. (1996) and none of the induced abortions were done for reasons of fetal abnormality. Fetal ovaries from the therapeutic termination of pregnancies (from 12 to 22 wpf) had to display normal histological features before they were included in the study. Our study was approved by the Biomedicine Agency (number PFS12-002) and all women gave their informed consent.
Xenograft protocol
Each pair of ovaries, obtained from legally aborted fetuses, was cut into four pieces each before being grafted into female immunodeficient mice. Four pieces were selected randomly and transplanted into control and treated recipient mice. Isoflurane gas inhalation anesthesia was used during the grafting protocol. Following experiments, performed to identify the best grafting site, sub-cutaneous grafting and grafting into the kidney capsule (Abir et al., 2003; Hernandez-Fonseca et al., 2004) were found to complicate the harvesting of healthy grafted tissues. Ultimately based on reduced surgery invasiveness, efficient graft recovery, and adequate angiogenesis, grafting into the back muscle, as previously described with adult human ovaries (Soleimani et al., 2008) , was favored. Thus, for each mouse, four pieces were inserted into the back muscle, 10 mm away from the incision site, using fine curved Vannas scissors (Moria, France) to make a 3 -5-mm deep incision. Finally, body wall and skin incisions were closed. All procedures were performed under aseptic conditions. DMRTA2 role in human female germline development
In vivo RNA interference protocol Synthetic HPLC purified siRNAs (sense and antisense strands) were purchased from Sigma-Aldrich (Evry, France). SiRNAs were chosen from a pre-designed bank of siRNA, designed using the Rosetta-powered siRNA design algorithm (Rosetta Inpharmatics) and were blasted to verify that they did not match any other sequences, including murine Dmrta2 (Dmrt5) (Supplementary data, Fig. S4B ) or other human DMRTs notably DMRTB1 (DMRT6) and DMRTC2 (DMRT7) (data not shown). Sequences are shown in Table I . The efficiency of each siRNA alone, and that of a mixture, composed of all three siRNAs was verified using HEK293 cells, a human kidney cell line expressing DMRTA2 (DMRT5) (Supplementary data,  Fig. S4A ). Five pairs of fetal human ovaries (9.4, 9.9, 10.0, 10.3 and 10.8 wpf) were grafted into nude mice and peritoneal injections were initiated 4 weeks after, to target the meiosis initiation window. For each pair of ovaries, two recipient animals were grafted and received daily injections of an siRNA universal negative control (Mission w siRNA Universal negative Control, Sigma-Aldrich, Evry, France) or a mixture of three siRNAs, specifically targeting the human sequence of DMRTA2 (DMRT5). Preliminary experiments were performed to compare the effect of siRNA injections as a function of dose (6 or 30 mg/kg/day) and treatment duration (3 or 10 days). Higher doses (30 mg/kg/day) were found to generate immune systemic reactions in some recipient mice (n ¼ 2). Mice were immediately sacrificed to avoid suffering (third day). Real-time quantitative PCR (RT -qPCR) analysis indicated robust inhibition of DMRTA2 (DMRT5). The dose of 6 mg/kg/day, over a period of 10 days was eventually defined as being efficient, while generating no adverse systemic reactions. Twenty-four hours after the last injection, animals were sacrificed and grafts were recovered for histological and immunohistochemical analyses or gene expression studies.
Histology and immunohistochemistry
After collection, human ovary grafts were fixed in Bouin's fluid or 10% neutral formalin. The fixed tissues were dehydrated, embedded in paraffin and cut into 5 mm-thick sections.
For histology, sections were stained with hematoxylin and eosin (H&E). Germ cells on each section were identified on the basis of their histological features, as previously described Poulain et al., 2012) . Normalization was achieved by dividing the number of germ cells (at least 1000 cells counted) in each fragment by the area, to obtain a germ cell density.
Immunohistochemistry was performed using commercially available primary antibodies: anti-FUT4 (1/100, MC 480 Cell Signaling, Saint Quentin en Yvelines, France), anti-gH2AX antibody (1/500, Euromedex, Mundolsheim, France), anti-cleaved caspase-3 antibody (1/100, ASP175 Cell signaling, Saint Quentin en Yvelines, France), anti-pan-TP63 antibody (1/100 4A4, Santa Cruz Biotechnology, CA, USA), anti-DDX4 antibody (1/500, Abcam, Cambridge, UK), anti-POU5F1 antibody (1/200, Santa Cruz Biotechnology) and anti-PCNA (1/10 000, PC10, Abcam,), as previously described (Le ouffant et al., 2010; Poulain et al., 2012) . DNA fragmentation was detected by terminal dUTP nick-end labeling (TUNEL) of DNA (ApopTag w Peroxidase in situ apoptosis detection kit, S7100, Millipore, France). Germ cells were counted in sections distributed along the graft (at least 1000 stained and/or unstained germ cells), using Histolab software (Microvision Instruments, Evry, France).
Murine germ cell sorting
Germ cells were purified by flow cytometry (fluorescence activated cell sorter) (Beckman Coulter, Brea, CA, USA; MoFlo) using a pool of 13.5 dpc ovaries from Oct4-GFP mice, crossed with the NRMI mouse strain (Yoshimizu et al., 1999) as previously described (Souquet et al., 2012) .
Real-time quantitative PCR
The total RNA from grafted and ungrafted ovarian pieces, murine fetal and post-natal gonads, sorted Oct-4 positive and negative cells and HEK293 cell cultures were extracted using the RNeasy mini-kit (Qiagen, Courtaboeuf, France), and reverse transcription was carried out with the high capacity cDNA reverse transcription kit (Applied Biosystems, Courtaboeuf, France), according to the manufacturer's instructions.
In order to measure the expression of multiple genes during human gonadal development, total RNA from fetal ovaries and testes were also extracted using the RNeasy mini-kit (Qiagen Courtaboeuf, France), followed by a reverse transcription and whole transcriptome amplification (Quantitect whole transcriptome cDNA Amplification, Qiagen, Coutaboeuf, France). A single ovary was used for 14.5, 17.0 and 21.8 wpf and a single testis for 6, 7.9 and 9.6 wpf. RNA from similarly aged gonads were pooled: for the ovaries a first pool was constituted with 6.5; 6.8 and 6.9 wpf leading to an estimated age of 6.7 wpf, the second was 7.9; 7.6 and 7.3 wpf (estimated age of 7.6 wpf); the third was 8.8 and 8.6 wpf (estimated age of 8.7 wpf); the fourth was 10.1 and 10.0 wpf (estimated age of 10.1 wpf). The fifth was a pool of three different ovaries aged of 11.0 wpf. For the testes the pool was constituted with 10.6 and 11.0 wpf (estimated age of 10.8 wpf).
The 7900HT Fast real-time PCR system (Applied Biosystems, Foster City, CA) and SYBR-green or Taqman labeling were used for quantitative RT -PCR (RT -qPCR). The comparative DDcycle threshold method was used to determine the relative quantities of mRNA using ACTB (b-actin) or PPIA (cyclophilin A) mRNA as endogenous reporters. Results are presented as a percentage of the maximum (i.e. the highest expression is defined as 100%). Each RNA sample was analyzed in duplicate. The sequences of oligonucleotides used with SYBR-green detection were designed with Primer express Software (Table II) .
Statistical analysis
Each data point represents the mean + SEM of a minimum of at least three independent experiments. Data were analyzed using either ANOVA or Student's t-test. P-values of ,0.05 were considered statistically significant.
Results
DMRT expression in human fetal gonads
Human fetal gonads from the first and second trimesters of pregnancy were grouped according to developmental stage (ovaries ranging from a mean age of 6.7 -21.8 wpf and testes ranging from a mean age of 6-10.8 wpf), and the expression profiles of the eight DMRT members were determined by RT -qPCR (Fig. 1) . No obvious change in the expression patterns throughout development was observed for DMRT1, DMRTA1 (DMRT4) and DMRTC1 (DMRT8) neither as a function of sex, nor age. DMRT2, DMRT3, DMRTA2 (DMRT5), DMRTB1 (DMRT6) and DMRTC2 (DMRT7) were expressed exclusively in the ovaries. In the human fetal ovary, the very first meiotic cells are observed at about 11 wpf and many cells continue to initiate meiosis up to and beyond 
wpf. Interestingly, DMRTA2 (DMRT5), DMRTB1 (DMRT6) and DMRTC2 (DMRT7) harbored expression profiles, which correlated with the timing of meiotic initiation and were comparable to that of STRA8, the gatekeeper of the mitotic-meiotic switch. DMRT2 was mostly expressed at earlier (from 7 to 11 wpf), and DMRT3 at later stages of development (from 17 wpf). Similar results were obtained with a different set of gonads ranging from 5.5 to 32 wpf (n ¼ 18) confirming the expression profile of DMRTA2 (DMRT5), DMRTB1 (DMRT6), DMRTC2 (DMRT7) (Supplementary data, Fig. S1 ).
Dmrta2, Dmrtb1 and Dmrtc2 are expressed in female murine germ cells during fetal life
Next, we speculated that if some DM domain genes play a significant role in the developing female germline, their expression may be conserved among mammals. Thus, we investigated the time course of expression of Dmrta2 (Dmrt5), Dmrtb1 (Dmrt6) and Dmrtc2 (Dmrt7) in female and male gonads from early fetal development to adulthood in mice. The age-related profile of Dmrta2 (Dmrt5) expression from fetal life to adulthood indicated that, as in humans, the expression correlates with female meiotic initiation in the mouse ( Fig. 2A) . Expression is elevated in the ovary during the early stages of development, peaking at 13.5 and 14.5 dpc, and regressing thereafter. In the male gonads, the expression levels of Dmrta2 (Dmrt5) remained low throughout fetal life and increased moderately during post-natal life (32.2% of the female maximum), starting at 10 dpp, which corresponds to the initiation of meiosis in male mice.
Murine gonad Dmrtb1 (Dmrt6) and Dmrtc2 (Dmrt7) expression profiles during fetal and post-natal life were comparable to that of Dmrta2 (Dmrt5) (data not shown). As before, these genes were specifically expressed in the ovary at 13.5 dpc (Fig. 2B ).
To determine whether Dmrta2 (Dmrt5), Dmrtb1 (Dmrt6) and Dmrtc2 (Dmrt7) are expressed in somatic or germ cells, cell sorting was performed using 13.5 dpc Pou5f1-GFP(DPE) murine ovaries, displaying green fluorescent protein expression in germ cells (Fig. 2C) . Cell sorting efficiency was assessed measuring specific germ and somatic cell markers (Ddx4 and Fst, respectively), in the GFP-positive (Pou5f1+) and negative (Pou5f12) fractions. Dmrta2 (Dmrt5), Dmrtb1 (Dmrt6) and Dmrtc2 (Dmrt7) appeared to be specifically expressed in germ cell fractions (Pou5f1+). Altogether this indicates that the expression profiles of Dmrta2 (Dmrt5), Dmrtb1 (Dmrt6) and Dmrtc2 (Dmrt7) are evolutionarily conserved and correlate to meiotic initiation. Interestingly, Dmrta1 (Dmrt4), the closest family member to Dmrta2 (Dmrt5), was poorly expressed in female fetal germ cells, although its expression was also demonstrated in the mouse embryonic ovary (Supplementary data, Fig. 2A and B) .
Inhibition of DMRTA2 expression using RNA interference
In order to investigate the role of DMRTA2 (DMRT5) in the human female germ line at the time of meiotic initiation, we established an original model combining ovarian xenografting and RNA interference. 
DMRTA2 role in human female germline development
We first investigated the robustness of the xenograft model with fetal ovaries collected in first trimester (8 -10 wpf) and implanted in mice for 4 -8 weeks. The development of the grafted tissue was then compared both to native first trimester ovaries ( Fig. 3A and B) and to older native ovaries harvested at 12 -22 wpf (Supplementary data, Fig. S3B ). Human ovarian grafts were successfully retrieved from 100% of grafted mice (n ¼ 35/35). When we compared the size of native ovaries harvested at 8-11 wpf (n ¼ 4) to the one of ovaries (n ¼ 3) grafted for 4 weeks, we found a clear increase from 0.32 + 0.05 to 1.04 + 0.05 mm 3 . Four weeks after grafting, germ cell density was similar in the graft to that observed in vivo, at a comparable stage of development, indicating normal germ cell survival and proliferation rates in the graft (Fig. 3A) . Detailed analysis of germ cell apoptosis using active caspase-3 and TUNEL staining revealed few labeled cells while measurement of germ cell proliferation through PCNA-staining identified numerous multiplying oogonia (respectively about 5 and 90%). Furthermore, germ cell molecular differentiation, defined by the loss of stem cell antigen FUT4 expression and the appearance of the differentiation marker DDX4, occurred in the graft, as expected, when compared with ungrafted control ovaries ( Fig. 3A and B) . Additionally, initiation of meiosis occurred in a proper timeframe. We observed the appearance of cells with typical chromatin features, corresponding to the various stages of meiotic prophase: fine threads with bead-like structures in leptonema, filaments gathered at a nuclear pole in the zygotene stage, compacted and thick threads corresponding to paired homologous chromosomes in the pachynema stage and fine threads with a nucleolus in the diplotene stage. Immunohistochemical studies confirmed the appearance of DDX4 in the graft (Fig. 3B) . Furthermore, gH2AX, which labels DNA-double strand breaks (DNA-DSB), that are predominately observed in the leptotene and zygotene stages, and TP63, a protein considered to be the guardian of the female germline genome (Livera et al., 2008) , which is normally apparent in late pachytene and diplotene stage oocytes, were also detected (Fig. 3B ). Ultimately in a few long-term grafted ovaries (n ¼ 4, from 7 to 9 weeks) we also observed many oocytes, surrounded by somatic cells, exhibiting typical primordial and primary follicle features (Supplementary data, Fig. S3A , representative sections of two grafted ovaries, and 3B, left native ovary harvested at 17 wpf and right 8 wpf ovary grafted for 8 weeks). In conclusion, the xenografting of human fetal ovaries into immunodeficient mice served as an in vivo model that maintained the morphological, histological and molecular development of the germ cells over several weeks.
Interestingly, in 4 weeks-grafted ovaries, DMRTA2 (DMRT5) expression reached similar levels to those observed in their ungrafted counterparts, from the second trimester of pregnancy (Fig. 3C) . Three different siRNAs, specifically targeting human DMRTA2 (DMRT5) (Supplementary data, Fig. S4B ) were simultaneously injected into recipient grafted mice, to inhibit the expression of this gene. Doses of 6 mg/kg/day yielded a Figure 1 DMRT expression in human fetal gonads. DM domain gene and STRA8 expressions were measured by quantitative RT -PCR in human fetal ovaries and testes. For ovaries, a pool of three gonads was used for mean ages 6.7, 7.6 and 11 weeks post-fertilization (wpf), a pool of two gonads for mean ages 8.7 and 10.1 wpf and one gonad for the age of 14.5, 17 and 21.8 wpf, respectively. For the testes, one gonad was used for the age of 6, 7.9 and 9.6 wpf and a pool of two gonads for mean age 10.8 wpf. Gene expressions were compared with ACTB expression and data are expressed as percentages of the maximum. The arrow indicates the point of entry into meiosis. strong inhibition (81%) of DMRTA2 (DMRT5) mRNA levels in the graft, while the mice remained healthy for the entire test period (10 days) (Fig. 3D) . Given that Dmrta2 (Dmrt5) is expressed in the kidney (Kim et al., 2003) , we verified that the siRNAs did not interfere with the expression of the murine transcript in this tissue (Fig. 3E) . In short, this model both faithfully mimics the physiological development of the human female germline at the critical mitotic-meiotic switch period and allows functional studies to be carried out through gene silencing strategies.
DMRTA2 inhibition impairs the growth and cellular differentiation of grafted ovaries
After 10 days of daily siRNA injections directed against DMRTA2 (DMRT5), we measured various parameters, to analyze the global development of the grafts. After graft recovery from sacrificed mice, grafts that had been exposed to DMRTA2 (DMRT5) siRNAs were observed to be smaller than those exposed to control siRNA (P , 0.05) (Fig. 4A) . Graft volume was decreased for all siDMRTA2-treated grafts (32-55% in comparison to controls). Surprisingly, neither germ cell density nor the rate of apoptosis, measured by cleaved caspase 3 staining, was affected by the inhibition of DMRTA2 (DMRT5) (Fig. 4A and B, HE and Cleaved caspase-3). DNA fragmentation, a hallmark of apoptosis, also failed to reveal significant change in the germ cell apoptotic rate (Fig. 4B, TUNEL) . Measurement of PCNA-positive cells (Fig. 4B,  PCNA) , as an index of proliferation, identify no overt change neither in oogonia nor in somatic cells (respectively, 78 + 6% versus 87 + 20%, P ¼ 0.13 and 14 + 3% versus 19 + 4%, P ¼ 0.56 for untreated and treated germ and somatic cells, n ¼ 3). Hematoxylin/eosin staining demonstrated the presence of numerous meiotic cells in controls, whereas few meiotic oocytes were detected in grafts, which had been exposed to DMRTA2 siRNA (Fig. 4B, HE) . This may, in part, explain the decrease in graft size, as the diameter (and thus the volume) of meiotic germ cells is larger than that of oogonia. Indeed the diameter of leptotene/zygotene stage oocytes is 1.7-fold greater than that of oogonia (mean 21.1 mm versus mean 12.1 mm, respectively), which yields a 4.9-fold greater volume (Fig. 4C ).
DMRTA2 regulates female germ cell molecular differentiation
To further analyze the effect of DMRTA2 (DMRT5) inhibition on the development of human female germ cells, we analyzed various markers of undifferentiated (NANOG) (Kerr et al., 2008) , differentiating (DAZL and DDX4) (Anderson et al., 2007) , pre-meiotic and meiotic (STRA8 and SPO11) germ cells (Le Bouffant et al., 2010) (Fig. 5A ). The expression of NANOG was unchanged while that of the markers of more differentiated germ cells was significantly decreased. The expression of betacatenin (CTNNB1), a marker associated with female somatic cell differentiation was unaltered (Chassot et al., 2008) . Interestingly, the expression of both DMRTB1 (DMRT6) and DMRTC2 (DMRT7), which correlates with meiotic entry, was equally impaired, though the siRNAs used did not target their sequences. Altogether, our data suggest that DMRTA2 (DMRT5) could promote germ cell differentiation shortly prior to meiotic initiation. (B) Dmrtb1 and Dmrtc2 expressions, in a pool of murine 13.5 dpc NMRI female and male gonads, were measured by RT-qPCR. Gene expression was normalized to the murine Actb and data are expressed as percentages of the maximum (n ¼ 3 gonads). At this age point, the expression of these 2 DM domain genes was specific to female gonads. (C) Ddx4, Fst and Dmrta2, Dmrtb1 and Dmrtc2 gene expressions were measured in germ cell purified fractions (green fluorescent protein [GFP]+) (black column) and somatic cell fractions (GFP2) (white column) obtained from 13.5 dpc ovaries from Pou5f1-GFP mice, using RT -qPCR (mean + SEM; n ¼ 3; expression as percentages of the maximum normalized against Actb) (*P , 0.05, **P , 0.01 in the paired Student's t-test).
DMRTA2 role in human female germline development
This hypothesis was tested by labeling the least differentiated germ cells that express FUT4, and meiotic cells, using gH2AX, a hallmark of meiotic DNA-DSB. DMRTA2 (DMRT5) inhibition triggered an increase of 2-fold of FUT4-positive germ cells. Simultaneously we observed a 43% decrease in the percentage of gH2AX-positive germ cells (n ¼ 5, Fig. 5B ). This confirmed a likely arrest around meiotic entry.
Discussion
Our study, for the first time, identifies the presence, and reveals the importance of DMRTA2 (DMRT5) in normal human female embryonic germ cell development. DMRTA2 (DMRT5) appears to be essential in allowing the appropriate differentiation of oogonia, shortly prior to their entry into meiosis.
It is striking to note that DMRTA2 (DMRT5), DMRTB1 (DMRT6), DMRTC2 (DMRT7) (this study, Kim et al., 2003) and DMRT1 (Kim et al., 2003; Jorgensen et al., 2012) , all apparently have conserved expressions in pre-meiotic female germ cells, in mouse and human developing ovaries. We reported for the first time, the expression of DMRTA2 (DMRT5), DMRTB1 (DMRT6) and DMRTC2 (DMRT7) in the human fetal ovary. Additionally, we detected the expression of DMRT1 throughout human ovary development. These data are in line with a recent study, reporting DMRT1 protein expression in fetal human germ cells (Jorgensen et al., 2012) . In mouse embryonic gonads, the expression of Dmrt1, Dmrta2 (Dmrt5) and Dmrtc2 (Dmrt7) has previously been reported (Kim et al., 2003) . Interestingly, the expression of Dmrtb1 (Dmrt6) was not demonstrated in the embryonic ovary. Moreover our study demonstrated the specific expression of Dmrta2 (Dmrt5), Dmrtb1 (Dmrt6) and Dmrtc2 (Dmrt7) in murine female germ cells. Other studies previously reported the presence of Dmrt1 in murine fetal germ cells (Krentz et al., 2013) . Of note, Dmrta1 (Dmrt4), the closest paralog of Dmrta2 (Dmrt5), has previously been detected in mouse embryonic ovaries (Kim et al., 2003) and we observed no obvious expression in germ cells. Although mRNA expression does not warrant the presence of an active protein and some DMRT family members might not always be translated (Kawamata et al., 2007) , it is likely that at least DMRT1 (Jorgensen et al., 2012) and DMRTA2 (DMRT5, this study) proteins are present in the human gonads. Indeed, we observed a staining for DMRTA2 (DMRT5) protein specifically in germ cells in sections of human fetal ovaries (Supplementary data, Fig. S5 ). However, future DMRTA2 role in human female germline development work will need to address the presence and activities of the other DMRT family members at the protein levels (Kawamata et al., 2007) .
These results suggest that these four DMRT genes may influence the progression of pre-meiotic female germ cell development, within a very narrow timeframe. This apparent co-expression of several DMRT family members is intriguing, as DMRT members target similar DNA motifs (Murphy et al., 2007) . A tentative explanation may be that some of these genes might regulate other Dmrt genes, as in the case of Dmrt1 that was shown to bind to numerous Dmrt promoters . Furthermore it is noteworthy that sites bound by DMRT members are rather similar and that they may act as heterodimer, notably DMRT1 and DMRTA2 (DMRT5) (Murphy et al., 2007) . Whether a hierarchy exists between these members has yet to be elucidated. We observed that inhibition of the expression of DMRTA2 (DMRT5) impaired the expression of DMRTB1 (DMRT6) and DMRTC2 (DMRT7). As such, this observation led us to propose that DMRTA2 (DMRT5) governs other DMRT expressions. However, as germ cell development is arrested, it is no surprise that expression of DMRTB1 (DMRT6) and DMRTC2 (DMRT7) is impaired. This would be true of any other genes whose expression increases during that developmental process (i.e. DDX4).
Altogether, we observed that the presence of cellular and molecular markers of meiotic prophase I was reduced or delayed after inhibition of DMRTA2 (DMRT5). Additionally, we also documented a conserved expression of factors such as NANOG, associated with undifferentiated germ cells (Kerr et al., 2008) , and a decrease in the expression of markers, such as DAZL and DDX4, which are associated with pre-meiotic differentiation (Anderson et al., 2007) . These data were consistent with the observation that many germ cells retained features of undifferentiated cells, such as FUT4, and few germ cells initiated meiosis based on gH2AX staining and chromatin features. Although we described a reduction in STRA8 expression, with no change in germ cell density, it remains doubtful that DMRTA2 (DMRT5) directly regulates STRA8, as this role has been proposed for the DMRT1 paralog (Krentz et al., 2011) . Indeed, it is perhaps more likely that DMRTA2 (DMRT5) acts on an earlier stage of meiotic commitment. It is currently accepted that meiotic commitment is a two-step process. The first step involves the acquisition of intrinsic factors enabling cells to initiate meiosis, notably (black column) and siDMRTA2 (white column) treated grafts, measured by RT -qPCR: CTNNB1, a somatic marker; NANOG, a stem cell marker found in oogonia; DAZL and STRA8 required for meiotic entry; SPO11, a meiotic marker, DDX4 normally expressed in differentiating germ cells, DMRTB1 and DMRTC2. Gene expressions are expressed as a percentage of the maximum and normalized to PPIA (*P , 0.05, **P , 0.01 and ***P , 0.001 in the paired Student's t-test). (B) FUT4 and gH2AX were detected by immunohistochemistry in sections from siCTR and siDMRTA2 treated grafts (*P , 0.05 in the paired Student's t-test). Black arrows indicate the negative germ cells and open arrows denote the positive germ cells. through the expression of DAZL (Lin et al., 2008) . The second step entails the reception of a meiosis-inducing signal that triggers STRA8 expression, ultimately leading to meiotic entry (Le Bouffant et al., 2010; Childs et al., 2011) . Based on our data DMRTA2 (DMRT5) may regulate the acquisition of the intrinsic factors, as we observed a decrease in DAZL expression upon DMRTA2 (DMRT5) inhibition. Additionally in Dmrt1 2/2 ovaries (Krentz et al., 2013) , an increase in the expression of markers associated with pluripotency was described. This supports the increase in undifferentiated germ cells (FUT4-positive), observed in this study. However, future studies will be required to identify the direct molecular targets of DMRTA2 (DMRT5) in female germ cells. Nevertheless, one cannot rule out the impact of DMRTA2 (DMRT5) inhibition on germ cell proliferation or apoptosis. Although we observed no increase in apoptotic markers in germ cells, it is possible that transitory apoptotic processes were undetectable using these methods or that germ cell death occurred through a different pathway as this as previously been proposed in early oocytes (De Felici et al., 2008) . Conversely, the robust decrease in the size of grafts exposed to DMRTA2 siRNA may result from perturbed proliferation. This last hypothesis is supported by observed decreases in germ cell numbers. Indeed if the cell volume is decreased and the density unchanged, the number of germ cells must be reduced. Such anti-proliferative or pro-apoptotic processes, which specifically target differentiating germ cells, may be alternative impact sites of the effect of DMRTA2 (DMRT5) inhibition. In line with our first hypothesis, this might merely be the consequence of the arrested germ cell differentiation.
Secondly, we developed an original model of xenografted first trimester fetal human ovaries, which could be used in tandem with an RNA interference strategy. This model supported the survival of ovarian cells for over 8 weeks with appropriate development of the female germline, when compared with ungrafted ovaries at equivalent developmental stages. The time course and rate of oogonia proliferation, initiation and progression of meiosis and the follicle formation were comparable to those of in vivo organs (i.e. ungrafted ovaries). To our knowledge, this is the first report of first trimester-ovary xenografts and the first characterization of a model that allows the initiation of human meiosis in vivo. Xenografting of human fetal organs, including ovaries and testes, was first described in 1974 Skakkebaek et al., 1974) . These, and subsequent studies (Abir et al., 2000 (Abir et al., , 2003 (Abir et al., , 2009 Sadeu et al., 2006; Oktem and Oktay, 2007; Lan et al., 2010; Mitchell et al., 2010; Wu et al., 2010) all used second trimester ovaries (i.e. already at the follicle stage) from 20 wpf and after. Adult ovarian tissue xenografts are also used to investigate the impact of cryopreservation on follicular growth (Aubard, 2003) . Altogether grafting human ovaries appears to be a reliable tool, which allows the development of the female germline, regardless of developmental stage.
Importantly we also report here for the first time, the coupled use of RNA interference and xenografting of human fetal tissues. The impact of target gene inhibition on tumor cells, using in vivo RNA interference, has been well documented (Landen et al., 2006; Delloye-Bourgeois et al., 2009; Koyanagi et al., 2013) . Successful gene inhibition, in grafts, using siRNA relies, in part, on the development of robust vascularization, which connects rapidly with the ovarian capillary and irrigates the entire tissue. Such vascularization is, naturally, absent in the organ model, the other documented model for studying human fetal organs (Baker and Neal, 1974; Poulain et al., 2012; Tartarin et al., 2012) . The inhibition of gene expression, to investigate mammalian development, has usually been carried out using transgenic murine models. The model described in our study offers an invaluable opportunity to explore human organ development. Such a tool should eventually allow the investigation of those genetic diseases, which are thought to cause the impairment of normal tissue development, or examine the mechanisms of action of endocrine disruptors on the development of the human fetal ovary. Though our model has only been used for the developing human ovary in this instance, nonetheless, its value should not be underestimated, not least because, the slow development of the human ovary, when compared with that of the mouse, may be advantageous, in terms of potentially allowing a more precise identification of the developmental stages regulated by targeted genes. Furthermore, it is also noteworthy that here we inhibited the expression of the human DMRTA2 (DMRT5) gene, without interfering with that of its mouse homolog. This result is especially interesting as the Dmrta2 (Dmrt5) mutation in mouse is incompatible with life (Saulnier et al., 2013) . One must also consider this strategy as an efficient means to by-pass embryonic lethality of numerous mutations in mice. Ultimately, the use of RNA interference also has limitations and cannot fully obliterate the expression of a target gene.
Altogether, we believe that the described ovarian xenograft model should prove useful for future investigations of human germline, and other cell, development. The model faithfully mimics the development of germ cells from the mitotic stage to the follicular stage, thus allowing the elucidation of the mitotic/meiotic transition and meiotic progression. Secondly, the model facilitates functional studies to investigate the involvement of given genes in these processes.
In conclusion, using an original xenograft model, we highlighted the contribution of DMRTA2 (DMRT5) to human germ cell development. Future studies should clarify the mechanisms of action and the interplay of various DM domain genes in these cells.
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